Poor R-Wave Progression and Long-Term Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)

Brief title: Poor R-Wave Progression in MESA Outcomes

José Nunes de Alencar[1,2], Sandro Pinelli Felicioni[1], Mariana Fuziy Nogueira De Marchi[1].

1. Electrocardiography Unit. Instituto Dante Pazzanese de Cardiologia. São Paulo. Brazil.
2. Research Division. Instituto Dante Pazzanese de Cardiologia. São Paulo. Brazil.

Data availability statement: De-identified MESA data from Exams 1–5 with adjudicated events through calendar year 2015 are available from the NHLBI BioLINCC repository (Accession HLB00640824a) upon approved application and data-use agreements. Access for commercial entities is tiered per participant consent.

Conflicts of Interest Disclosure: There is no conflict of interest to disclose.

Ethics approval: All participants provided written informed consent and the protocol was approved by the institutional review boards of each participating center.

Clinical trial registration: ClinicalTrials.gov Identifier NCT00005487.

Total word Count: 4683

AI use disclosure: We used ChatGPT (OpenAI) to (1) assist with R code debugging/structuring (e.g., improving data-cleaning functions, model-reporting tables, and plotting syntax) and (2) provide language editing to improve clarity and flow in American English. All study design, analyses, interpretation, and

original scientific content were conceived and written by the authors. The authors verified all code and results and take full responsibility for accuracy. No identifiable patient information was shared with the AI; any material used for editing was de-identified or paraphrased.

Author Contributions

- Conceptualization: José Nunes de Alencar Neto (JNdA)
- Project Administration: JNdA,
- Writing – Original Draft: JNdA, Sandro Pinelli Felicioni (SPF) and Mariana De Marchi (MDM)
- Writing – Review & Editing: JNdA , SPF and MDM
- Guarantor of the Article: JNdA accepts full responsibility for the integrity of the study and the manuscript.

All authors had full access to the data, substantially contributed to manuscript revision, and approved the final version.

CORRESPONDING AUTHOR

José Nunes de Alencar Neto

Instituto Dante Pazzanese de Cardiologia

Avenida Dr. Dante Pazzanese No. 500, Vila Mariana

São Paulo 04012-091

Brazil

Tel: +551150856457

jose.alencar@dantepazzanese.org.br

ABSTRACT

Background: Poor R-wave progression (PRWP) on the 12-lead electrocardiogram has been linked to adverse outcomes. Its prognostic value in a contemporary, multi-ethnic population without baseline coronary artery disease (CAD) is unclear.

Methods: We analyzed 6,323 adults (mean age 61.9±10.2 years; 54% women) from the Multi-Ethnic Study of Atherosclerosis after excluding pre-excitation, major conduction disease, Q-wave infarction, and missing covariates. PRWP was defined as R-wave amplitude ≤3 mm in V3 with RV3>RV2 and was present in 202 participants (3.2%). Outcomes were all-cause mortality, cardiovascular (CV) death, and major adverse cardiovascular events (MACE: nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke). Cox models adjusted for age, sex, race/ethnicity, hypertension, and diabetes.

Results: Over a median 14.1 years (IQR, 13.5–14.7), 1,138 deaths, 256 CV deaths, and 515 MACE occurred. Among PRWP participants, there were 52 deaths (25.7%), 8 CV deaths (4.0%), and 16 MACE (7.9%). In prespecified models, PRWP was not associated with CV death (hazard ratio [HR] 0.87; 95% CI, 0.43–1.76; P=0.690) or MACE (HR 0.94; 95% CI, 0.57–1.54; P=0.796) and showed a borderline association with all-cause mortality (HR 1.31; 95% CI, 0.99–1.73; P=0.059), driven by non-CV deaths. Adjustment for smoking and emphysema attenuated estimates (all-cause HR 1.19; 95% CI, 0.90–1.58; P=0.229). A PRWP×sex interaction was significant for MACE (likelihood-ratio test P=0.002), driven by higher stroke incidence in women; interactions by race/ethnicity were not significant.

Conclusions: In a large, CAD-free, multi-ethnic cohort, isolated PRWP was uncommon and did not confer independent risk for CV death or MACE over 14 years. The borderline excess in all-cause mortality was non-CV and diminished after accounting for smoking and emphysema.

Keywords: poor R-wave progression, electrocardiography, multi-ethnic cohort, cardiovascular mortality, MESA

INTRODUCTION

Evidence from disease-specific cohorts suggests that poor R wave progression (PRWP) may lead to adverse outcomes. In the general population, the Health 2000 survey, a nationally representative Finnish cohort of 5,613 adults, demonstrated a 5.1% prevalence overall (7.0% in women vs. 2.7% in men). During a median of 5.8 years of follow-up, PRWP conferred a two-fold increase in both all-cause and cardiovascular mortality among women, an effect that persisted after adjustment for age, hypertension, diabetes, and established ischemic heart disease (adjusted HR 2.00, 95 % CI 1.28–3.13). In men, however, the association was attenuated and nonsignificant.(1) More recently, a 24-year community study linked PRWP to sudden cardiac death (SCD) (adjusted HR 2.13, 95% CI 1.34–3.39) and amplified cardiac-mortality risk among participants with known CAD.(2)

Despite these signals, a contemporary systematic review concluded that available studies suffer from heterogeneous PRWP definitions, inconsistent outcome ascertainment, and pervasive selection bias, impeding firm inferences about diagnostic accuracy.(3) The review underscored a need for large, multiethnic, community-based cohorts in which standardized ECG acquisition, rigorous adjudication of events, and comprehensive covariate adjustment could clarify the true prognostic weight of PRWP.

The Multi-Ethnic Study of Atherosclerosis (MESA) meets these criteria. Initiated in 2000, MESA enrolled 6814 adults aged 45–84 years who were free of clinical cardiovascular disease at baseline, intentionally sampling equal proportions of women and men across four self-identified race/ethnic groups—White, Black, Hispanic, and Chinese—from six U.S. field centers.(4) Uniform digital 12-lead ECGs, detailed imaging of subclinical atherosclerosis, and adjudicated cardiovascular events have been collected over two decades of surveillance. MESA therefore provides an unparalleled framework to investigate (a) the prevalence of PRWP in a multiethnic population initially free of overt heart disease, (b) the independent association between PRWP and subsequent all-cause death, cardiovascular death, and (c) potential effect modification by sex, race/ethnicity.

Accordingly, we used MESA to quantify its independent association with all-cause mortality and major adverse cardiovascular events (MACE), and whether any association is modified by sex.

METHODS

Study Population

MESA is a prospective, population-based cohort that enrolled 6,814 adults aged 45–84 yr who were free of clinically apparent cardiovascular disease at baseline (July 2000–September 2002) from six U.S. field centers.(4) All participants gave written informed consent, and each center's institutional review board approved the protocol. Clinical cardiovascular disease (CVD) was an exclusion criterion for the parent study; candidates reporting physician-diagnosed myocardial infarction, angina, coronary revascularization, stroke or transient ischemic attack, heart failure, pacemaker or ICD implantation, or valve surgery were ineligible. Additional exclusions included body weight > 136 kg, active cancer treatment, or plans to relocate within five years. All participants provided written informed consent, and each field center's institutional review board approved the protocol.

For the present analysis we used baseline data and censored follow-up at 31 December 2015. Participants were excluded if they had electrical confounders. (a) ECGs labelled by Minnesota coding as Wolff–Parkinson–White were discarded because pre-excitation alters initial depolarization vectors. (b) Those showing complete bundle-branch block, bifascicular block or other major intraventricular conduction delay were excluded for the same reason. (c) Tracings annotated by the automated algorithm as "probable prior anterior myocardial infarction" on the basis of pathologic Q waves were also removed, as a deep Q wave prevents reliable identification of diminished R-wave growth. Finally, (d) records missing any key covariate required for multivariable

adjustment (age, sex, diabetes status, hypertension status, or any relevant ECG data) were excluded.

Electrocardiography and Definition of Poor R-Wave Progression

Standard 12-lead ECGs were recorded digitally at 25 mm/s and 10 mm/mV using a Marquette MAC-PC system (GE Healthcare). All tracings were transmitted electronically to the MESA ECG Reading Center (Wake Forest University), where certified analysts applied Minnesota coding; ≥ 97 % of leads met the protocol's quality threshold. R-wave amplitudes were measured automatically, and values for lead V3 were exported for analysis. PRWP was defined as an R-wave amplitude ≤ 0.30 mV (≤ 3 mm) in lead V3 and an R-wave amplitude in V3 that exceeded that in V2 (R V3 > R V2).

Covariate Assessment

Age, sex and race/ethnicity were self-reported at baseline. Blood pressure was obtained with a standardized protocol; hypertension was defined as systolic pressure ≥ 140 mm Hg, diastolic pressure ≥ 90 mm Hg, or use of antihypertensive medication. Diabetes was defined as fasting plasma glucose ≥ 126 mg/dL or use of glucose-lowering medication. Body-mass index was measured with standard MESA procedures. Baseline spirometry (FEV₁, FVC, FEV₁ and percent-predicted values) was available in a subset. Because spirometry does not quantify static lung volumes (e.g., total lung capacity or residual volume), it cannot diagnose pulmonary hyperinflation; therefore, we did not treat spirometric indices as direct measures of hyperinflation in the primary analyses.

Ascertainment of Outcomes

Participants or relatives were contacted every 9–12 months to identify hospitalizations and deaths; medical records were reviewed, and events were

adjudicated by a centralized committee.(5) Outcomes for this analysis were (a) all-cause mortality, (b) cardiovascular death, defined as adjudicated death due to atherosclerotic coronary heart disease, stroke, atherosclerotic disease other than coronary or stroke, or other cardiovascular causes, and (c) MACE, defined as the composite of nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke, analyzed as time to first occurrence of any component

Statistical Analysis

Continuous variables are reported as mean ± SD and compared with unpaired t-tests; categorical variables are summarized as counts (percentages) and compared with χ^2 tests. For baseline covariates, P values were generated from logistic-regression models adjusted for both age and sex.

Time-to-event analyses were performed with Cox proportional-hazards regression. The primary, prespecified model adjusted for age, sex, race/ethnicity, hypertension, and diabetes—covariates selected a priori. After reviewing the baseline data, we built a second, exploratory model adding characteristics that differed materially between PRWP and non-PRWP groups and that have biologic links to both precordial voltage and cardiovascular risk. Proportional-hazards assumptions were confirmed with Schoenfeld residuals. Effect modification by sex was assessed by adding a PRWP × sex interaction term and comparing nested models with a likelihood-ratio test; sex-specific hazard ratios (HRs) were taken from this interaction model. Given that previous research predominantly involved White Scandinavian cohorts, we also conducted an unplanned, exploratory analysis to assess the potential effect modification by self-identified race/ethnicity. A multiplicative PRWP × race term (four categories) was added to the fully adjusted Cox model and compared with the base model. All effects are reported as adjusted HRs with 95 % confidence intervals (CIs).

MACE was defined as the first occurrence of nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke (time to first component). Two-by-two contingency tables compared event frequencies between PRWP cases and

controls; Pearson's χ² test was used when all expected cell counts were ≥ 5, otherwise Fisher's exact test was applied.

To illustrate time-to-event differences after covariate adjustment, we generated survival curves directly from the fully adjusted Cox model (age, sex, race/ethnicity, hypertension, diabetes). The curves, shown with point-wise 95 % confidence bands, represent the survival that would be expected for each group if they shared an identical distribution of covariates. Because the estimates are standardized across the full cohort, conventional numbers-at-risk tables are not applicable.

Analyses were performed in R version 4.5.0 (R Foundation for Statistical Computing). All reported P values are two-sided, and statistical significance was defined as P < 0.05.

RESULTS

Participant Characteristics

Of 6,814 participants enrolled in MESA, we sequentially excluded 491 (1 Wolff-Parkinson-White pattern, 297 bundle-branch or other major conduction disturbances, 124 major Q-wave MIs, 69 missing key covariates), leaving 6,323 participants for analysis (Figure 1). The cohort's mean age was 61.9 ± 10.2 years; 3,427 were women (54.2 %) and 2,896 were men (45.8 %). Self-identified race/ethnicity was 37.8 % White (n = 2,390), 27.7 % African American (n = 1,750), 22.4 % Hispanic (n = 1,414), and 12.2 % Chinese American (n = 769).

Poor R-wave progression was present in 202 participants (3.2 %) overall—136/3,427 women (4.0 %) and 66/2,896 men (2.3 %). Table 1 details other baseline characteristics and univariate age/sex–adjusted comparisons between the PRWP and non-PRWP groups. Relative to controls, PRWP cases were more frequently current smokers (23 % vs 13 %) and were six-fold more likely to report physician-diagnosed emphysema (7.9 % vs 1.3 %). They also had marginally lower mean LDL-C (112 mg/dL vs 118 mg/dL) and slightly higher

HDL-C, but the absolute lipid differences were small (< 6 mg/dL) and not considered clinically meaningful (Table 1).

Association of PRWP with Outcomes

During a median follow-up of 14.1 years (IQR, 13.5–14.7 years), we observed 1,138 deaths from any cause (18.0%), 256 cardiovascular deaths (4.0%) and 515 MACE events (8.1%) under the prespecified definition (first occurrence of nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke). Among participants with PRWP, there were 52 all-cause deaths (25.7%), 8 cardiovascular deaths (4.0%) and 16 MACE events (7.9%) (Table 2). Model-adjusted survival curves for freedom from all-cause death, cardiovascular death and MACE are shown in Figure 2. In the prespecified model—adjusted for age, sex, race/ethnicity, hypertension, and diabetes—PRWP showed a borderline association with all-cause mortality (HR 1.31; 95% CI, 0.99–1.73; P=0.059), no association with cardiovascular death (HR 0.87; 95% CI, 0.43–1.76; P=0.690), and no association with MACE (HR 0.94; 95% CI, 0.57–1.54; P=0.796).

Because smoking and emphysema differed materially between PRWP and non-PRWP groups and are biologically linked to both thoracic voltage and cardiovascular risk, an exploratory model added current smoking and self-reported emphysema. The hazard ratio for all-cause death fell to 1.19 (95% CI, 0.90–1.58; P=0.229), cardiovascular death (HR 0.83; 95% CI, 0.41–1.68; P=0.596) and MACE remained neutral (HR 0.89; 95% CI, 0.54–1.47; P=0.649). Lipid fractions were not introduced given clinically trivial between-group differences and lack of a direct mechanistic link to anterior R-wave amplitude.

Effect modification analysis

We assessed multiplicative interaction on the primary adjustment set (age, sex, race/ethnicity, diabetes, hypertension). For all-cause mortality, adding a PRWP×sex term did not improve model fit (LRT P=0.615). Sex-stratified estimates were directionally similar and not statistically significant: women HR

1.22 (95% CI, 0.81–1.82; P=0.338) and men HR 1.40 (95% CI, 0.95–2.07; P=0.085).

For MACE, the PRWP×sex interaction was statistically significant (likelihood-ratio test P=0.002). Women with PRWP had a directionally higher risk (HR 1.62; 95% CI, 0.94–2.79; P=0.081), whereas men had a lower risk (HR 0.24; 95% CI, 0.06–0.96; P=0.043). This divergence was driven by stroke incidence within the PRWP group (women 8.8% vs men 0%; 12/136 vs 0/66; P=0.0098). For cardiovascular death, the PRWP×sex interaction was not significant (LRT P=0.447); sex-specific estimates were null (women HR 1.11; 95% CI, 0.45–2.72; P=0.822; men HR 0.64; 95% CI, 0.20–2.00; P=0.439).

PRWP×race interaction was not significant for any outcome (likelihood-ratio test: all-cause mortality P=0.600; cardiovascular death P=0.200; MACE P=0.588). Race-stratified hazard ratios were uniformly non-significant.

DISCUSSION

In this community-based cohort of more than six thousand adults initially free of clinical cardiovascular disease, isolated poor R-wave progression was present in 3.2% of participants. After fourteen years of surveillance and multivariable adjustment, PRWP was not associated with cardiovascular mortality or MACE and showed a borderline excess in all-cause mortality, attributable to non-cardiovascular deaths. In a secondary model that additionally adjusted for current smoking and self-reported emphysema—two imbalanced, biologically plausible confounders—the association with all-cause mortality attenuated further (HR 1.19; 95% CI, 0.90–1.58; P=0.229).

Regarding MACE, we observed effect modification by sex (LRT P=0.002): women with PRWP had a higher, non-significant risk (HR 1.62; 95% CI, 0.94–2.79), whereas men had a lower risk (HR 0.24; 95% CI, 0.06–0.96). The difference was driven by stroke within PRWP (women 8.8% vs men 0%; P=0.0098). For all-cause mortality, the interaction was not significant (LRT P=0.615) and sex-specific estimates were similar in direction and non-

significant. Cardiovascular death did not differ by PRWP in either sex (LRT P=0.447).

The Health 2000 survey reported that PRWP doubled total and cardiovascular mortality in women over six years, even after multivariable adjustment.(1) Schröder and colleagues linked PRWP to sudden cardiac death (SCD) in the 24-year Mini-Finland follow-up (HR 2.13), together with elevated risks of cardiac death (HR 1.75) and all-cause mortality (HR 1.29). Notably, their CAD subgroup (n = 807) showed an even stronger hazard: PRWP tripled SCD (HR 2.62) and nearly doubled cardiac mortality (HR 1.71), associations that persisted after removal of Q-wave infarcts (HR 2.96 for SCD). By contrast, their CAD-free subgroup displayed no excess SCD risk and presented increase in cardiac death only (HR 1.64). In contrast to Health 2000, which reported higher cardiovascular and all-cause mortality in women with PRWP, MESA did not show any increase in cardiovascular mortality in either sex. The borderline excess in all-cause mortality was explained by non-cardiovascular deaths and was further attenuated after adjustment for smoking and emphysema.

The discrepant prognostic findings among the Health 2000 survey(1), the Mini-Finland study(2), and the present MESA analysis can be attributed to marked differences in the underlying study populations. First, coronary artery disease status diverged. Health 2000 and Mini-Finland enrolled participants irrespective of prevalent CAD, and the latter confirmed angiographic disease in approximately one eighth of its cohort. MESA, in contrast, excluded any clinical CAD at baseline. The Finnish reports therefore evaluated a population in which PRWP frequently co-existed with established myocardial scar or ischemia, whereas MESA assessed PRWP in the absence of overt structural heart disease.

Second, baseline age distributions were dissimilar. Health 2000 and Mini-Finland both began follow-up at a mean age of roughly 51 years, whereas the median age of the MESA PRWP group was 63 years. Despite this older starting point—and thus higher absolute risk—MESA showed no excess mortality or MACE associated with PRWP, indicating that age alone does not account for the Finnish associations once CAD is removed.

Third, exposure to tobacco varied. Regular smoking was present in about 30 % of PRWP men and 20 % of PRWP women in Health 2000, and a comparable prevalence was recorded in Mini-Finland among participants without angiographic CAD. In MESA, only 23 % of PRWP cases were current smokers, and inclusion of smoking status in the multivariable model further attenuated the hazard ratio.

Finally, MESA uniquely captured self-reported emphysema, a condition that can depress anterior voltages via lung hyperinflation. Emphysema was reported by 8 % of PRWP cases versus 1 % of controls, and adjustment for this variable, together with smoking, moved the point estimate closer to unity. Neither Finnish study collected systematic data on chronic obstructive lung disease. Although advanced emphysema with cor pulmonale can produce rapid R-wave progression by inducing right-ventricular hypertrophy, our emphysema data were self-reported and baseline echocardiography was unavailable, limiting assessment of that mechanism. Additionally, pulmonary hyperinflation could plausibly diminish R wave amplitudes in precordial leads and generate PRWP.(6) Future research could integrate lung-volume metrics or CT-based markers with spirometry to determine whether physiologic hyperinflation is a driver of reduced anterior voltages and apparent PRWP.

The present findings are also consistent with the absence of credible diagnostic evidence.(7) In a recent scoping review, we sought studies that could quantify the accuracy of PRWP for detecting prior anterior myocardial infarction.(3) Every eligible research displayed severe selection bias: Zema's studies enrolled only patients who already had PRWP and then looked for scar by angiography or vectorcardiogram, but lacking a true control group with normal R-wave progression. As a result, the published "sensitivities" and "specificities" are inherently biased and essentially uninterpretable, leaving the true diagnostic accuracy of PRWP for old anterior infarction unknown.

Taken together, these findings indicate that the prognostic signal attributed to PRWP in earlier work is not intrinsic to the voltage pattern itself but rather to the clinical setting in which the pattern was recorded. In a cohort stringently free of overt CAD—and rigorously adjusted for smoking and pulmonary

hyperinflation—PRWP behaves as a benign ECG variant. Our null findings call into question the current practice of automatically flagging isolated PRWP as 'abnormal' on computer-generated ECG reports. When the pattern appears in patients without established CAD or overt structural heart disease, additional testing is unlikely to change management. This contention is consistent with the low positive predictive value (≈7 %) for angiographic CAD reported in population-based studies(8) and highlights the risk of unnecessary downstream investigations

Future directions

First, prospective cohorts should record electrode-position metadata or use body-surface mapping to establish the temporal stability of PRWP and distinguish true electrical change from placement artefact. Second, studies that pair precordial voltages with lung-volume surrogates - thoracic CT metrics, formal spirometry, or impedance plethysmography - are needed to clarify whether physiologic hyperinflation, rather than myocardial injury, is the dominant driver of reduced anterior voltage in community settings. Beyond these technical issues, high-quality diagnostic-accuracy research is needed. Specifically, adequately powered cohorts with a uniform PRWP definition should test its value for (a) detecting previous anterior myocardial infarction against a gold-standard imaging reference, (b) identifying reduced left-ventricular ejection fraction, and (c) flagging infiltrative or genetic cardiomyopathies in which low precordial voltages may precede overt structural change.

Limitations

Several considerations must be acknowledged. First, PRWP was ascertained from a single baseline tracing; transient lead misplacement or day-to-day biologic variability could have misclassified a small fraction of participants. Although MESA technicians followed a standardized electrode-placement protocol and quality audits revealed <2 % gross errors, even minor cranial displacement of V￿/V￿ can convert a normal anterior pattern into PRWP.

While sequential ECGs are available in MESA, we did not model the development or resolution of PRWP over time. Incident PRWP on follow-up tracings may simply reflect changes in lead placement rather than new myocardial injury; a rigorous longitudinal analysis would therefore require electrode-position metrics that are not part of the dataset.

Second, R-wave amplitude is influenced by thoracic impedance and lung volume. Conditions that increase chest wall thickness or hyperinflate the lungs—obesity, chronic obstructive pulmonary disease, emphysema—were not fully captured in baseline covariates and could have attenuated anterior voltages independent of myocardial substrate. Although spirometry was available for a subset of participants, spirometry alone cannot characterize hyperinflation, so we did not interpret spirometric values as definitive evidence of hyperinflation or emphysema.

Third, only 202 individuals met the PRWP criterion, limiting power for granular subgroup analyses—particularly in men and within individual race/ethnicity strata. Finally, although the extensive covariate set and stability across sensitivity models argue against major confounding, residual or unmeasured factors cannot be fully excluded in any observational analysis.

Conclusions

In a contemporary, multi-ethnic cohort of 6,323 adults who were free of clinical cardiovascular disease at enrollment, isolated poor R-wave progression was uncommon (3.2 %) and—for up to 14 years of follow-up—carried no independent association with either all-cause mortality or major adverse cardiovascular events after adjustment for age, sex, race/ethnicity, hypertension and diabetes. Additional adjustment for the two imbalanced, biologically plausible confounders—current smoking and self-reported emphysema—further attenuated the already-neutral point estimates, and a formal interaction test showed no meaningful difference in risk between women and men. Earlier positive studies appear driven by populations enriched for coronary disease and other high-risk features.

REFERENCES

1. Anttila I, Nikus K, Nieminen T, Jula A, Reunanen A, Salomaa V, et al. Prevalence and prognostic value of poor R-wave progression in standard resting electrocardiogram in a general adult population. The Health 2000 Survey. Ann Med. março de 2010;42(2):123–30.

2. Schröder LC, Holkeri A, Eranti A, Haukilahti MAE, Kerola T, Kenttä TV, et al. Poor R-wave progression as a predictor of sudden cardiac death in the general population and subjects with coronary artery disease. Heart Rhythm. 15 de fevereiro de 2022;19(6):952–9.

3. de Alencar JN, Amorim EF, Scheffer MK, Felicioni SP, De Marchi MFN. Poor evidence for poor R wave progression in coronary disease: A scoping review. J Electrocardiol. 1º de maio de 2024;84:145–50.

4. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 1º de novembro de 2002;156(9):871–81.

5. Blaha MJ, DeFilippis AP. Multi-Ethnic Study of Atherosclerosis (MESA). JACC. 29 de junho de 2021;77(25):3195–216.

6. Rodman DM, Lowenstein SR, Rodman T. The electrocardiogram in chronic obstructive pulmonary disease. J Emerg Med. 1990;8(5):607–15.

7. Gami AS, Holly TA, Rosenthal JE. Electrocardiographic poor R-wave progression: analysis of multiple criteria reveals little usefulness. Am Heart J. julho de 2004;148(1):80–5.

8. Kim SH, Kwak MH, Kim HJ, Nam GB, Choi KJ, Kim YH. Prevalence and positive predictive value of poor R-wave progression and impact of the cardiothoracic ratio. Korean Circ J. 2009/10/28 ed. outubro de 2009;39(10):418–22.

Sources of Funding

The Multi-Ethnic Study of Atherosclerosis (MESA) is supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHLBI or the National Institutes of Health.

Acknowledgments

We thank the MESA investigators, staff, and participants for their valuable contributions. A full list of participating MESA investigators and institutions is available at http://www.mesa-nhlbi.org.

TABLES

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal R-wave progression N = 6,121[1]	PRWP N = 202[1]	P (adj.)*
Age (yr)	61.8 (10.2)	63.0 (10.5)	0.123
Body-mass index (kg/m²)	28.3 (5.4)	28.3 (6.9)	0.823
Total cholesterol (mg/dL)	194.7 (35.7)	191.3 (32.1)	0.049
LDL cholesterol (mg/dL)	117.7 (31.6)	112.1 (28.2)	0.014
HDL cholesterol (mg/dL)	51.0 (14.8)	54.9 (15.7)	0.031
Physical activity (h/day)	12.6 (5.9)	12.6 (5.3)	0.877
QRS duration (ms)	91.3 (9.6)	91.6 (10.1)	0.062
Sex			<0.001
Female	3,291 (54%)	136 (67%)	
Male	2,830 (46%)	66 (33%)	

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal progression N = 6,121[1]	R-wave PRWP N = 202[1]	P (adj.)*
Ethnicity			<0.001
White	2,295 (37%)	95 (47%)	
Chinese American	759 (12%)	10 (5.0%)	
African American	1,674 (27%)	76 (38%)	
Hispanic	1,393 (23%)	21 (10%)	
Hypertension	2,679 (44%)	103 (51%)	0.150
Blood-pressure category JNC			0.158
Optimal	2,604 (43%)	78 (39%)	
Normal	1,042 (17%)	31 (15%)	
High-Normal	949 (16%)	28 (14%)	
Stage 1 HTN	1,091 (18%)	40 (20%)	

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal progression N = 6,121[1]	R-wave **PRWP** N = 202[1]	P (adj.)*
Stage 2 HTN	314 (5.1%)	21 (10%)	
Stage 3 HTN	119 (1.9%)	4 (2.0%)	
Diabetes			0.774
Normal	4,533 (74%)	149 (74%)	
Impaired fasting glucose	836 (14%)	24 (12%)	
Diabetes (untreated)	162 (2.6%)	5 (2.5%)	
Diabetes (treated)	590 (9.6%)	24 (12%)	
Smoking status			<0.001
Never	3,106 (51%)	84 (42%)	
Former	2,217 (36%)	71 (35%)	
Current	780 (13%)	46 (23%)	

Table 1. Age- & Sex-Adjusted Baseline Characteristics by PRWP Status P-values (adj.): Age adjusted for sex; sex adjusted for age; all other variables adjusted for both age and sex.

Characteristic	Normal R-wave progression N = 6,121[1]	PRWP N = 202[1]	P (adj.)*
Self-reported emphysema			<0.001
No	6,031 (99%)	186 (92%)	
Yes	82 (1.3%)	16 (7.9%)	
Unknown	7 (0.1%)	0 (0%)	
β-Blocker medication	535 (8.7%)	22 (11%)	0.433
Atrial fibrillation	1 (<0.1%)	0 (0%)	0.979
LVH (ECG-based)	610 (10.0%)	21 (10%)	0.797
LVH (CMR-based)	1,340/4,525 (30%)	42/138 (30%)	0.679

[1] Mean (SD); n (%); n/N (%)

Legend: Baseline Characteristics by Poor R-Wave Progression Status. Continuous variables are reported as mean (SD); categorical variables as n (%), except LVH (CMR-based), shown as n/total (%) to denote the number with cardiac-MRI data available.

PRWP is defined as R-wave amplitude ≤ 3 mm in lead V3 and R-wave V3 > R-wave V2.

P (adj.) values come from logistic-regression models that provide: (i) Age adjusted for sex; (ii) Sex adjusted for age; (iii) every other variable adjusted for both age and sex.

LVH (CMR-based): LV mass index > 90 g/m² (men) or > 77 g/m² (women).

LVH (ECG-based): positive Sokolow-Lyon or Peguero-Lo Presti voltage criterion.

JNC = Joint National Committee blood-pressure category.

TABLE 2.

Outcome	PRWP (n=202) — no./total (%)	Controls (n=6,121) — no./total (%)	P value†
All-cause mortality	52/202 (25.7)	1,086/6,121 (17.7)	0.0036
Cardiovascular death‡	8/202 (4.0)	248/6,121 (4.1)	0.9484
MACE	16/202 (7.9)	499/6,121 (8.2)	0.9051
• Myocardial infarction	3/202 (1.5)	259/6,121 (4.2)	0.0540
• Resuscitated cardiac arrest	1/202 (0.5)	28/6,121 (0.5)	0.6108
• Stroke	12/202 (5.9)	246/6,121 (4.0)	0.1744

Legend: Values are no./total (%). P values from χ² or Fisher's exact tests compare crude proportions between PRWP and controls. Although all-cause mortality was higher in PRWP, it was not statistically significant in Cox models adjusted for age, sex, race/ethnicity, hypertension, and diabetes (HR 1.31; 95% CI, 0.99–1.73; P=0.059). ‡Cardiovascular death was defined as adjudicated death due to atherosclerotic coronary heart disease, stroke, other atherosclerotic cardiovascular disease, or other cardiovascular causes. MACE was the first occurrence of nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke.

FIGURES

Figure 1.

Legend: Study flow diagram.

Figure 2.

Legend: Model-adjusted survival curves for all-cause mortality, cardiovascular death, and major adverse cardiovascular events (MACE). Survival probabilities for participants with normal R-wave progression (Controls, red) and poor R-wave progression (PRWP, blue) were estimated from multivariable Cox proportional-hazards models adjusted for age, sex, race/ethnicity, hypertension,

and diabetes. Shaded areas represent pointwise 95% confidence intervals derived by direct standardization of the covariate distribution. Numbers-at-risk are omitted because standardized curves average follow-up time across the full cohort.